TW202304951A - 結合鐵調素模擬物 - Google Patents

結合鐵調素模擬物 Download PDF

Info

Publication number
TW202304951A
TW202304951A TW111112892A TW111112892A TW202304951A TW 202304951 A TW202304951 A TW 202304951A TW 111112892 A TW111112892 A TW 111112892A TW 111112892 A TW111112892 A TW 111112892A TW 202304951 A TW202304951 A TW 202304951A
Authority
TW
Taiwan
Prior art keywords
lys
substituted
cys
solvate
pharmaceutically acceptable
Prior art date
Application number
TW111112892A
Other languages
English (en)
Chinese (zh)
Inventor
葛雷格里 伯爾尼
艾索克 班達利
婕 張
馬克 斯麥斯
中川 陳
Original Assignee
美商領導醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商領導醫療公司 filed Critical 美商領導醫療公司
Publication of TW202304951A publication Critical patent/TW202304951A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW111112892A 2021-04-01 2022-04-01 結合鐵調素模擬物 TW202304951A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163169538P 2021-04-01 2021-04-01
US202163169533P 2021-04-01 2021-04-01
US202163169527P 2021-04-01 2021-04-01
US63/169,538 2021-04-01
US63/169,533 2021-04-01
US63/169,527 2021-04-01
US202263325323P 2022-03-30 2022-03-30
US63/325,323 2022-03-30

Publications (1)

Publication Number Publication Date
TW202304951A true TW202304951A (zh) 2023-02-01

Family

ID=83456776

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111112892A TW202304951A (zh) 2021-04-01 2022-04-01 結合鐵調素模擬物

Country Status (7)

Country Link
US (1) US20250277012A1 (enExample)
EP (1) EP4314017A4 (enExample)
JP (1) JP2024513392A (enExample)
AU (1) AU2022249095A1 (enExample)
CA (1) CA3213688A1 (enExample)
TW (1) TW202304951A (enExample)
WO (1) WO2022212696A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ.ベー. インターロイキン-23受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
EP4472996A4 (en) * 2022-02-02 2025-11-26 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1451211A2 (en) * 2001-03-30 2004-09-01 University of Copenhagen Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
EP4091624A1 (en) * 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
WO2015200916A2 (en) * 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
US20190002503A1 (en) * 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018128828A1 (en) * 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
CA3089868A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
PH12022550510A1 (en) * 2019-09-03 2023-09-04 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
AU2021315564A1 (en) * 2020-07-28 2023-02-09 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Also Published As

Publication number Publication date
EP4314017A4 (en) 2025-09-10
WO2022212696A1 (en) 2022-10-06
AU2022249095A1 (en) 2023-10-12
US20250277012A1 (en) 2025-09-04
JP2024513392A (ja) 2024-03-25
CA3213688A1 (en) 2022-10-06
EP4314017A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
US11472842B2 (en) Analogues of hepcidin mimetics with improved in vivo half lives
TW202304951A (zh) 結合鐵調素模擬物
JP2026012422A (ja) コンジュゲート型ヘプシジン模倣体
JP7849383B2 (ja) コンジュゲートされたヘプシジン模倣物
EP4501952A2 (en) Conjugated hepcidin mimetics
WO2022212698A1 (en) Conjugated hepcidin mimetics
WO2023150630A2 (en) Conjugated hepcidin mimetics
WO2023150618A2 (en) Conjugated hepcidin mimetics
CN117730089A (zh) 结合型铁调素模拟物
CN117813313A (zh) 结合型铁调素模拟物
CN116457000A (zh) 缀合的铁调素模拟物
EA053112B1 (ru) Конъюгированные миметики гепсидина
EA048412B1 (ru) Конъюгированные миметики гепсидина